HC Wainwright Comments on Inozyme Pharma Q1 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Inozyme Pharma in a note issued to investors on Friday, January 10th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05.

Several other equities analysts have also commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Raymond James assumed coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $12.00 price objective on shares of Inozyme Pharma in a report on Friday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Inozyme Pharma presently has a consensus rating of “Buy” and a consensus target price of $17.25.

Inozyme Pharma Price Performance

Shares of NASDAQ INZY opened at $2.00 on Monday. Inozyme Pharma has a fifty-two week low of $1.97 and a fifty-two week high of $7.80. The company has a market cap of $128.48 million, a PE ratio of -1.28 and a beta of 1.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The business has a 50-day simple moving average of $3.02 and a two-hundred day simple moving average of $4.38.

Hedge Funds Weigh In On Inozyme Pharma

A number of institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC grew its holdings in Inozyme Pharma by 5.0% during the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock worth $21,623,000 after acquiring an additional 198,216 shares during the period. Samlyn Capital LLC grew its stake in shares of Inozyme Pharma by 15.0% during the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock worth $14,943,000 after purchasing an additional 437,622 shares during the period. Affinity Asset Advisors LLC increased its holdings in shares of Inozyme Pharma by 8.1% during the 2nd quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock valued at $12,739,000 after purchasing an additional 213,733 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Inozyme Pharma by 154.1% in the 2nd quarter. Millennium Management LLC now owns 1,787,947 shares of the company’s stock valued at $7,974,000 after purchasing an additional 1,084,341 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Inozyme Pharma by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock valued at $6,126,000 after purchasing an additional 19,499 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.